Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Key Points Common meaning BPC-157 plus TB-500 Scientific status Marketing nickname, not a standardised formulation BPC-157 15-residue synthetic peptide TB-500 Seven-residue acetylated thymosin beta-4 fragment Direct stack evidence No robust controlled trial identified Main evidence problem Full thymosin beta-4 research is often mislabelled as TB-500 evidence UK authorisation None identified Sport status Both components prohibited under WADA rules What Is the Wolverine Stack
majority of TBI and stroke studies Mice Used for transgenic Alzheimers models (APP, APP/PS1) and excitotoxicity studies Humans Multiple clinical trials in stroke, dementia, and TBI populations Cell culture Cortical neurons, hippocampal cultures, endothelial cells for mechanistic studies Research Limitations & Regulatory Status Critical Gaps in Current Evidence Despite over 1,000 preclinical studies and numerous clinical trials, Cerebrolysin faces substantial translational challenges that significantly limit its therapeutic utility
Therapeutic Goods Administration: Product and Consumer Information
no clinical trial data exist for this pairing, though their complementary amylin and incretin-based mechanisms provide a theoretical scientific rationale
US$ 28.11
US$ 20.71
US$ 24.39
US$ 29.09
US$ 29.40
US$ 22.59
